A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
List view / Grid view
Victoria Rees (Drug Target Review)
Filter the results
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
A new article has outlined the body's inflammatory response to COVID-19 infection, saying that lipid mediators derived from omega-3 fatty acids could prevent life-threatening inflammation.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Researchers have shown that adding the RPL6 protein to malaria vaccines was successful at protecting mice against the condition.
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
In a new article, researchers highlight the need for treatments to combat the potentially lethal overreaction of the immune system in the progression of COVID-19.
Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
A group of researchers has found that SARS-CoV-2 may not spread by faecal-to-oral transmission, but is able to infect the gastrointestinal tract via the TMPRSS2 and TMPRSS4 enzymes.
Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
A new paper describes the first full study of the epigenetics of human tumour organoids, suggesting this could be used to develop novel oncology treatments.